8-K: Stemtech Announces Strategic Merger with Seacret Direct and Proposed Reverse Takeover of Eevia Health

Stemtech Corporation is set to merge with Seacret Direct and pursue a reverse takeover of Eevia Health, aiming to create a vertically integrated global health and wellness leader.

Summary

• Stemtech Corporation has entered into a merger agreement with Seacret Direct, also known as Viago, and has signed a non-binding letter of intent for a reverse takeover (RTO) of Eevia Health Plc.
• The merger with Seacret Direct will result in Seacret becoming a wholly-owned subsidiary of Stemtech, with Seacret's equity holders receiving preferred stock convertible into 50% of Stemtech's fully diluted common stock.
• The proposed RTO of Eevia Health would involve Eevia acquiring the assets of Stemtech and Seacret, with Stemtech owning approximately 85% of Eevia and existing Eevia shareholders owning the remaining 15%.
• The combined entity is expected to benefit from Eevia's manufacturing capabilities, Stemtech's stem cell nutrition products, and Seacret's lifestyle and wellness membership offerings.
• The merger with Seacret is expected to double Stemtech's revenue, and the combined entity anticipates significant revenue growth in 2025 with strategic synergies.
• The transactions are subject to various conditions, including due diligence, shareholder approvals, and the negotiation of definitive agreements.

Sentiment

Score: 8

Explanation: The document conveys a highly positive outlook with significant growth potential through strategic mergers and acquisitions. The company is positioning itself in high-growth markets and has a clear vision for the future. However, there are risks associated with the transactions and the need to raise capital.

Positives

• The merger with Seacret is expected to double Stemtech's revenue.
• The RTO with Eevia Health provides access to manufacturing capabilities and expands the product portfolio.
• The combined entity is positioned to capitalize on the growing wellness, stem cell, and travel markets.
• The merger and RTO are expected to create significant synergies and cost efficiencies.
• The combined companies will have a global reach with operations in 40+ countries and a large customer base.
• The leadership team of the combined companies has extensive experience in the direct sales, nutraceutical, and pharmaceutical industries.

Negatives

• The transactions are subject to various conditions, including due diligence, shareholder approvals, and the negotiation of definitive agreements, which could lead to delays or termination.
• The final valuation and terms of the RTO are still subject to negotiation.
• The company needs to raise a minimum of $10,000,000 in closing financing.
• There is a risk of litigation that could impact the merger or RTO.
• The company has an outstanding case against the company from 2019 in which a former board member prior to the Companys Bankruptcy filed a lawsuit alleging unpaid salary.

Risks

• The merger agreement can be terminated if conditions are not met by June 25, 2025.
• The RTO is subject to regulatory compliance and a new listing process on the Spotlight Stock Market.
• The company may not be able to raise the necessary bridge and closing financing.
• There is a risk that the proposed business combination disrupts current plans and operations.
• The company may not be able to recognize the anticipated benefits of the proposed business combination.
• The company may face challenges in integrating the operations of Stemtech, Seacret, and Eevia.
• The company is subject to risks related to competition, changes in laws and regulations, and potential litigation.

Future Outlook

The combined companies are positioned for significant growth in the global health, wellness, and longevity market, with a focus on expanding their global footprint and driving revenue growth through strategic synergies and innovative product offerings. The company expects to see significant revenue growth in 2025.

Management Comments

• Charles S. Arnold, Chairman of Stemtech Corporation, stated that the three-way consolidation is a game-changing event for all stakeholders.
• Charles S. Arnold believes that with VIGOs global network of affiliated customers, members and affiliates driving referrals and sales inherent synergies while streamlining our operations, we should deliver shareholder value and will position ourselves in the wellness and lifestyle industries.

Industry Context

This announcement reflects a trend of consolidation in the health and wellness industry, with companies seeking to expand their product offerings, market reach, and manufacturing capabilities through mergers and acquisitions. The focus on vertically integrated operations and global expansion is also consistent with broader industry trends.

Comparison to Industry Standards

• The merger and RTO strategy is similar to other companies in the health and wellness sector that are seeking to expand their market share and product offerings through acquisitions.
• The focus on vertical integration is a common strategy in the industry to control costs and ensure quality.
• The company's goal of achieving significant revenue growth in 2025 is in line with the growth expectations of other companies in the wellness and lifestyle industries.
• The company's focus on the stem cell market is similar to other companies that are investing in innovative technologies in the health and wellness sector.
• The company's global expansion strategy is similar to other companies that are seeking to capitalize on the growing demand for wellness products and services in international markets.

Management Changes

Legal Proceedings

• There is one outstanding case against the Company from 2019 in which a former board member prior to the Companys Bankruptcy filed a lawsuit alleging unpaid salary.

Stakeholder Impact

• Shareholders of Stemtech will see a change in ownership structure and potential for increased value through the merger and RTO.
• Employees of Stemtech, Seacret, and Eevia will be impacted by the integration of the companies and potential changes in roles and responsibilities.
• Customers of Stemtech and Seacret will have access to a broader range of products and services.
• Suppliers of Stemtech, Seacret, and Eevia will be impacted by the consolidation of the companies.
• Creditors of Stemtech and Seacret will be impacted by the merger and the assumption of liabilities by the combined entity.

Next Steps

• Complete due diligence on Eevia Health.
• Negotiate and finalize definitive agreements for the RTO.
• Obtain shareholder approvals for the merger and RTO.
• Raise bridge and closing financing.
• Integrate the operations of Stemtech, Seacret, and Eevia.
• Develop a mutually beneficial business plan.
• Rebrand the company.
• Transfer Stemtech's current business to a subsidiary.

Key Dates

Keywords

merger, reverse takeover, RTO, stemtech, seacret direct, viago, eevia health, wellness, stem cell nutrition, nutraceuticals, lifestyle, direct sales, manufacturing, global expansion